JP2022524974A5 - - Google Patents
Info
- Publication number
- JP2022524974A5 JP2022524974A5 JP2021552136A JP2021552136A JP2022524974A5 JP 2022524974 A5 JP2022524974 A5 JP 2022524974A5 JP 2021552136 A JP2021552136 A JP 2021552136A JP 2021552136 A JP2021552136 A JP 2021552136A JP 2022524974 A5 JP2022524974 A5 JP 2022524974A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- stereoisomer
- solvate
- acceptable salt
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962816698P | 2019-03-11 | 2019-03-11 | |
| US62/816,698 | 2019-03-11 | ||
| US201962835376P | 2019-04-17 | 2019-04-17 | |
| US62/835,376 | 2019-04-17 | ||
| US201962877741P | 2019-07-23 | 2019-07-23 | |
| US62/877,741 | 2019-07-23 | ||
| US201962931119P | 2019-11-05 | 2019-11-05 | |
| US62/931,119 | 2019-11-05 | ||
| PCT/US2020/021850 WO2020185755A1 (en) | 2019-03-11 | 2020-03-10 | Tyk2 inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022524974A JP2022524974A (ja) | 2022-05-11 |
| JP2022524974A5 true JP2022524974A5 (enExample) | 2023-03-20 |
| JP7586829B2 JP7586829B2 (ja) | 2024-11-19 |
Family
ID=72427699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021552136A Active JP7586829B2 (ja) | 2019-03-11 | 2020-03-10 | Ｔｙｋ２阻害剤およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20220177486A1 (enExample) |
| EP (1) | EP3938369A4 (enExample) |
| JP (1) | JP7586829B2 (enExample) |
| KR (1) | KR102899985B1 (enExample) |
| CN (1) | CN113811534B (enExample) |
| AU (1) | AU2020239026B2 (enExample) |
| BR (1) | BR112021017996A2 (enExample) |
| CA (1) | CA3132632A1 (enExample) |
| IL (1) | IL286248B2 (enExample) |
| WO (1) | WO2020185755A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS66346B1 (sr) | 2018-10-22 | 2025-01-31 | Alumis Inc | Inhibitori tyk2 i njihova upotreba |
| SG11202110523XA (en) * | 2019-03-26 | 2021-10-28 | Ventyx Biosciences Inc | Tyk2 pseudokinase ligands |
| US12410191B2 (en) | 2019-05-21 | 2025-09-09 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Macrolide derivatives, preparation method and application thereof |
| CN114929226B (zh) | 2019-11-08 | 2024-09-27 | 温缇克斯生物科学公司 | Tyk2假激酶配体 |
| IL301385A (en) * | 2020-09-16 | 2023-05-01 | Alumis Inc | TYK2 inhibitors and their use |
| WO2022117090A1 (zh) * | 2020-12-03 | 2022-06-09 | 成都科岭源医药技术有限公司 | 一种多环化合物及其制备方法和用途 |
| KR20240111312A (ko) | 2021-10-25 | 2024-07-16 | 카이메라 쎄라퓨틱스 인코포레이티드 | Tyk2 분해제 및 이의 용도 |
| CN119487037A (zh) * | 2022-03-16 | 2025-02-18 | 阿鲁米斯股份有限公司 | Tyk2抑制剂及其用途 |
| EP4493281A1 (en) * | 2022-03-16 | 2025-01-22 | Alumis Inc. | Tyk2 inhibitors and uses thereof |
| WO2023208244A1 (zh) * | 2022-04-29 | 2023-11-02 | 南京明德新药研发有限公司 | 大环类化合物及其应用 |
| EP4692096A4 (en) | 2023-03-31 | 2026-07-22 | Prime Gene Therapeutics Co Ltd | MACROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND ITS USE |
| WO2024222807A1 (en) * | 2023-04-27 | 2024-10-31 | Hangzhou Highlightll Pharmaceutical Co., Ltd | Novel macrocyclic heteroaryl derivatives as kinase inhibitors |
| WO2025194074A1 (en) * | 2024-03-15 | 2025-09-18 | Neuron23, Inc. | Kinase modulators and methods of use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7517882B2 (en) * | 2006-09-18 | 2009-04-14 | Polaris Group | Protein kinase inhibitors |
| WO2013001310A1 (en) * | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| ES2702126T3 (es) | 2013-12-10 | 2019-02-27 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa |
| WO2015112806A2 (en) * | 2014-01-24 | 2015-07-30 | Tp Therapeutics, Inc. | Diaryl macrocycles as modulators of protein kinases |
| RU2732405C2 (ru) * | 2015-07-02 | 2020-09-16 | Тёрнинг Поинт Терапьютикс, Инк. | Хиральные диарильные макроциклы в качестве модуляторов протеинкиназ |
| KR102782807B1 (ko) | 2015-11-18 | 2025-03-14 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물 |
| JOP20190092A1 (ar) * | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| JOP20190213A1 (ar) * | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| PT3658148T (pt) * | 2017-07-28 | 2024-08-26 | Turning Point Therapeutics Inc | Compostos macrocíclicos e utilizações dos mesmos |
| IL317854A (en) | 2017-07-28 | 2025-02-01 | Takeda Pharmaceuticals Co | TYK2 inhibitors and their uses |
| CN109053682B (zh) | 2018-07-27 | 2020-10-27 | 东南大学 | 一种tdo小分子抑制剂衍生物及其抗肿瘤偶联物和制备方法 |
| SG11202110523XA (en) * | 2019-03-26 | 2021-10-28 | Ventyx Biosciences Inc | Tyk2 pseudokinase ligands |
| CN114929226B (zh) | 2019-11-08 | 2024-09-27 | 温缇克斯生物科学公司 | Tyk2假激酶配体 |
-
2020
- 2020-03-10 US US17/438,329 patent/US20220177486A1/en not_active Abandoned
- 2020-03-10 AU AU2020239026A patent/AU2020239026B2/en active Active
- 2020-03-10 JP JP2021552136A patent/JP7586829B2/ja active Active
- 2020-03-10 CN CN202080034800.9A patent/CN113811534B/zh active Active
- 2020-03-10 WO PCT/US2020/021850 patent/WO2020185755A1/en not_active Ceased
- 2020-03-10 BR BR112021017996A patent/BR112021017996A2/pt unknown
- 2020-03-10 KR KR1020217032541A patent/KR102899985B1/ko active Active
- 2020-03-10 CA CA3132632A patent/CA3132632A1/en active Pending
- 2020-03-10 IL IL286248A patent/IL286248B2/en unknown
- 2020-03-10 EP EP20769748.3A patent/EP3938369A4/en active Pending
-
2025
- 2025-05-20 US US19/213,418 patent/US20250276977A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023541203A5 (enExample) | ||
| JP2022505987A5 (enExample) | ||
| JP2019031560A5 (enExample) | ||
| JP6466348B2 (ja) | スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用 | |
| JP2016506959A5 (enExample) | ||
| JP2013530142A5 (enExample) | ||
| JP2021509414A5 (enExample) | ||
| JP2014510774A5 (enExample) | ||
| JP6123097B2 (ja) | チエノピリミジン化合物を製造するための方法 | |
| JP2014503574A5 (enExample) | ||
| JP2023531709A5 (enExample) | ||
| MX2010007977A (es) | Derivados de carboxamidas azabiciclicas, su preparacion y su aplicacion en terapeutica. | |
| JP2020507589A5 (enExample) | ||
| JP2014509322A5 (enExample) | ||
| JP2010527985A5 (enExample) | ||
| JP2023036007A5 (enExample) | ||
| JP2021504326A5 (enExample) | ||
| AU2022366992A1 (en) | Integrin inhibitors and uses thereof in combination with other agents | |
| JP2019529460A5 (enExample) | ||
| JP2010505865A5 (enExample) | ||
| CN105452259A (zh) | 三环苯并氧杂硼化合物、其制备方法与应用 | |
| JP2023507569A5 (enExample) | ||
| JPWO2024177126A5 (enExample) | ||
| JP2024534420A5 (enExample) | ||
| JP2025513454A5 (enExample) |